Indication
Thyroid carcinoma
Thyroid carcinoma is a malignant neoplasm originating from the parenchymal cells of the thyroid gland, making it the most prevalent endocrine malignancy. Read more about Thyroid carcinoma
30 drugs 22 manufacturers
Drugs that treat it
Common Thyroid carcinoma therapies.
DOXORUBICIN (doxorubicin HCl)
DOXORUBICIN (doxorubicin HCl)
DOXORUBICIN (doxorubicin HCl)
DOXORUBICIN HCL
DOXORUBICIN (doxorubicin HCl)
DOXORUBICIN HCL
DOXORUBICIN HCL
DOXORUBICIN HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonThyroid carcinoma is a malignant neoplasm originating from the parenchymal cells of the thyroid gland, making it the most prevalent endocrine malignancy.
It predominantly arises from thyroid follicular epithelial cells, categorized into well-differentiated forms such as papillary and follicular carcinomas, poorly differentiated variants, and undifferentiated anaplastic carcinoma, as well as neuroendocrine calcitonin-producing parafollicular C cells, which give rise to medullary thyroid carcinoma.
Patients frequently present with an asymptomatic thyroid nodule, though advanced or aggressive lesions can manifest with regional lymphadenopathy, hoarseness from recurrent laryngeal nerve invasion, dysphagia, or distant metastases.
- nih.gov
Thyroid carcinoma is a malignant neoplasm originating from the parenchymal cells of the thyroid gland, making it the most prevalent endocrine malignancy It predominantly arises from thyroid follicular epithelial cells, categorized into well-differentiated forms such as papillary and follicular carcinomas, poorly differentiated variants, and undifferentiated anaplastic carcinoma, as well as neuroendocrine calcitonin-producing parafollicular C cells, which give rise to medullary thyroid carcinoma
- nih.gov
Thyroid carcinoma is a malignant neoplasm originating from the parenchymal cells of the thyroid gland, making it the most prevalent endocrine malignancy
- nih.gov
It predominantly arises from thyroid follicular epithelial cells, categorized into well-differentiated forms such as papillary and follicular carcinomas, poorly differentiated variants, and undifferentiated anaplastic carcinoma, as well as neuroendocrine calcitonin-producing parafollicular C cells, which give rise to medullary thyroid carcinoma Patients frequently present with an asymptomatic thyroid nodule, though advanced or aggressive lesions can manifest with regional lymphadenopathy, hoarse...
- nih.gov
It predominantly arises from thyroid follicular epithelial cells, categorized into well-differentiated forms such as papillary and follicular carcinomas, poorly differentiated variants, and undifferentiated anaplastic carcinoma, as well as neuroendocrine calcitonin-producing parafollicular C cells, which give rise to medullary thyroid carcinoma
- nih.gov
Patients frequently present with an asymptomatic thyroid nodule, though advanced or aggressive lesions can manifest with regional lymphadenopathy, hoarseness from recurrent laryngeal nerve invasion, dysphagia, or distant metastases
- nih.gov
Patients frequently present with an asymptomatic thyroid nodule, though advanced or aggressive lesions can manifest with regional lymphadenopathy, hoarseness from recurrent laryngeal nerve invasion, dysphagia, or distant metastases
Personalize your experience
Follow Thyroid carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.